Post-earnings recap
Reported
Wed, Aug 4, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that 10X Genomics Inc exceeded expectations on EPS, which likely contributed to the positive stock reaction of 3.51%. Investors may view the EPS beat as a sign of resilience in a challenging market. However, the lack of revenue data and forward guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.10 | N/A | +61.09% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a positive outlook on their product pipeline and market position. They acknowledged current challenges but remained focused on growth.
Management highlighted the strong demand for their products despite ongoing market challenges.
They emphasized their commitment to innovation and expanding their customer base.